Silence Therapeutics plc (SLN)
| Market Cap | 593.66M +139.4% |
| Revenue (ttm) | 615,000 -97.7% |
| Net Income | -59.95M |
| EPS | -1.27 |
| Shares Out | 60.21M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 844,344 |
| Open | 9.45 |
| Previous Close | 9.52 |
| Day's Range | 9.45 - 10.39 |
| 52-Week Range | 4.19 - 17.58 |
| Beta | 1.45 |
| Analysts | Buy |
| Price Target | 33.00 (+234.69%) |
| Est. Earnings | Nov 5, 2026 |
About SLN
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN3... [Read more]
Financial Performance
In 2025, Silence Therapeutics's revenue was $559,000, a decrease of -98.71% compared to the previous year's $43.26 million. Losses were -$88.61 million, 95.6% more than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for SLN stock is "Buy." The 12-month stock price target is $33.0, which is an increase of 234.69% from the latest price.
News
Silence Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
A clinical-stage biotech highlighted strong phase II results for its siRNA therapy divesiran in polycythemia vera, showing high efficacy, durable quarterly dosing, and a favorable safety profile. Regulatory and commercial preparations for phase III are underway, with a robust pipeline and CEO search ongoing.
Silence Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Proprietary siRNA platform advances a robust pipeline, highlighted by divesiran's strong phase II results in PV, with quarterly dosing moving to phase III. Full data and regulatory milestones are upcoming, while the pipeline expands into rare and cardiometabolic diseases.
Silence Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
The session highlighted advances in siRNA technology, with divesiran showing robust phase II efficacy and a favorable safety profile in PV. Plans are underway for a rapid phase III launch, supported by recent funding, with additional indications and commercial partnerships under evaluation.
Silence Therapeutics Slides: Corporate presentation
Silence Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 3, 2026.
Silence Therapeutics to Participate in Three September Investor Conferences
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today ...
Silence Therapeutics 13M share Secondary priced at $13.50
Jefferies, Morgan Stanley, Cantor Fitzgerald and William Blair acted as joint book running managers for the offering.
Silence Therapeutics 13M share Secondary priced at $13.50
Jefferies, Morgan Stanley, Cantor Fitzgerald and William Blair acted as joint book running managers for the offering.
Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional ADSs
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, (Nasdaq: SLN), (“Silence” or the “Company”), a global clinical-stage biotechnology company developing novel short interferin...
Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (“Silence” or the “Company”) , a global clinical-stage biotechnology company developing novel short interfering RNA (“siRNA”)...
Silence Therapeutics price target raised to $32 from $25 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Silence Therapeutics (SLN) to $32 from $25 and keeps an Overweight rating on the shares. Topline Phase 2 results for divesiran in…
Silence Therapeutics files to sell $150M in ADS’s
Jefferies, Morgan Stanley, Cantor and William Blair are acting as joint book-running managers for the proposed offering.
Silence Therapeutics Announces Proposed Public Offering of $150 Million of American Depositary Shares
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (“Silence” or the “Company”), a global clinical-stage biotechnology company developing novel short interfering RNA (“siRNA”) ...
Silence Therapeutics Transcript: Study result
The phase II SANRECO trial of divesiran in polycythemia vera showed 88% response versus 18% for placebo, with robust efficacy at both Q6- and Q12-week dosing and a favorable safety profile. Plans are underway for a phase III trial with quarterly dosing and further regulatory engagement.
Silence Therapeutics Press release: Study result
Silence Therapeutics issued a press release on August 10, 2026, disclosing material business information to investors.
Silence Therapeutics Slides: Study result
Silence Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 10, 2026.
Silence announces results from Phase 2 SANRECO trial met primary endpoint
Silence Therapeutics (SLN) announced positive topline results from the Phase 2 SANRECO trial of divesiran, a first-in-class siRNA, in 48 phlebotomy-dependent patients with polycythemia vera. The 36-we...
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today ...
Silence Therapeutics reports Q2 EPS (9c), consensus (17c)
Cash and cash equivalents were $72.1 million as of June 30, 2026. Pre-clinical pipeline updates: Generated additional preclinical data demonstrating the effect of SLN365 on lipids was reproduced and n...
Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its ...
Silence Therapeutics Earnings release: Q2 2026
Silence Therapeutics released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Silence Therapeutics Quarterly report: Q2 2026
Silence Therapeutics has published its Q2 2026 quarterly earnings report on August 10, 2026.
Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced a c...
Silence Therapeutics participates in a conference call with Cantor
Cantor holds a conference call with management on July 20 at 10 am. Webcast Link
Silence Therapeutics participates in a conference call with William Blair
Analyst Myles Minter holds a conference call with CMO Rambaran and Dr. Andrew Kuykendall of Moffitt Cancer Center on July 16 at 11 am hosted by William Blair. Webcast Link…
Cantor starts ‘materially undervalued’ Silence Therapeutics at Overweight
Cantor Fitzgerald analyst Prakhar Agrawal initiated coverage of Silence Therapeutics (SLN) with an Overweight rating and no price target Silence is a clinical-stage biotech focused on developing siRNA...